Stock Ratings / Health Care / ANIX / earnings

TLSA (55) NRXP (36) CLLS (49) EQ (42) ⌘ Pro Terminal →

Anixa Biosciences Inc. (ANIX) Next Earnings Date & Expected ±12.5% Move

$3.12 -5.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.08

Anixa Biosciences Inc. (ANIX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $114.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANIX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ANIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Anixa Biosciences Inc. (NASDAQ: ANIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.12 (-5.45% 1D, market cap $114.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ANIX ranks #777 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ANIX compare to TLSA and NRXP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLSA (Tiziana Life Sciences Ltd.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $115.1M) and NRXP (NRX Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $115.2M). Among the 5-stock peer group, ANIX leads on earnings multiple (N/A) while ANIX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANIX?

▼

Per ANIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0000715446), Anixa Biosciences Inc. generated $0 in revenue (-100.0% YoY), -$10.9M in net income, and -$7.2M in free cash flow against $15.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.08 (-1.17%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANIX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY ANIX SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 56.3 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.90-7.9% Next Q

Q2 (-2Q)

Grade E$2.67+12% Next Q

Q3 (-1Q)

Grade E$2.99+4.3% Next Q

Current

Grade E$3.12-9.2% Hist 90D α

Trajectory: E (24) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ANIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ANIX currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.97) and Max Pain ($3.28) forces dealer call-delta covering toward $5.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ANIX Beats Next Quarter EPS Consensus (Jan 29, 2027) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

NEXT EST. WINDOW: Jan 29, 2027 (~87 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.39 Expected Swing

MODEL EARNINGS SETUP GAUGE

ANIX Quantitative Pre-Earnings Setup: 32/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (32/100)Model Risk Weight (68/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-10-31	$0	-$10.9M	-$7.2M	52%
FY 2024	2024-10-31	$210.0K	-$12.6M	-$7.3M	52%
FY 2023	2023-10-31	$210.0K	-$9.8M	-$6.2M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANIX)

✓Walkthrough of ANIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.00%▲ ASCENDING CHANNEL

2026-10-30O $3.28H $3.35L $3.10C $3.12VOL 140.4K

RES: $4.29SUP: $2.63SMA50: $2.97SMA200: $2.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANIX Butterfly Map → + Track ANIX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANIX)

Health Care Rank #777 of 1016 ⚔️ TLSA vs ANIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANIX vs. TLSA, NRXP, CLLS, EQ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Anixa Biosciences Inc. (ANIX) ranks #777 by composite RQD confidence (32/100, grade E) and #642 by equity capitalization ($114.7M). Within this direct 5-issuer industry benchmark cohort, ANIX leads on earnings valuation at N/A trailing P/E, while ANIX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TLSA currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with ANIX at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANIX ACTIVE Anixa Biosciences Inc.	E	32/100	—	—	-35.0%	-5.45%	$114.7M	Benchmark Subject
TLSA Tiziana Life Sciences Ltd.	D+	55/100	—	—	—	-11.57%	$115.1M	/tlsa-vs-anix →
NRXP NRX Pharmaceuticals Inc.	D-	36/100	—	58.8%	-35.0%	-14.66%	$115.2M	/nrxp-vs-anix →
CLLS Cellectis S.A.	D	49/100	—	—	—	-7.69%	$117.6M	/clls-vs-anix →
EQ Equillium Inc.	D-	42/100	—	—	-35.0%	-3.52%	$111.3M	/eq-vs-anix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-10-31 • CIK 0000715446

In its most recent audited fiscal period (FY2025, filed 2025-10-31), Anixa Biosciences Inc. (ANIX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $210.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$10.9M, operating cash flow of -$7.2M, and free cash flow of -$7.2M (+2.2% YoY). On the balance sheet, ANIX closed FY2025 with $15.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-10-31	$0	-$10.9M	-$7.2M	-$7.2M	$15.2M	—
FY2024 (FY)	2024-10-31	$210.0K	-$12.6M	-$7.3M	-$7.3M	$18.9M	—
FY2023 (FY)	2023-10-31	$210.0K	-$9.8M	-$6.2M	-$6.2M	—	—

3. ANIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ANIX compare to TLSA and NRXP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ANIX?

Where is ANIX trading relative to its 50-day, 200-day, and 52-week technical levels?

ANIX last traded at $3.12 (-5.45% on volume of 140,662 shares), positioning the stock +5.05% above its 50-day simple moving average ($2.97) and +5.05% above its 200-day simple moving average ($2.97). Across its 52-week range of $2.32 to $5.46, ANIX sits at the 25.5% percentile with a 14-day RSI of 56.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.73 to $3.51).

ANIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ANIX's next earnings date?

Based on SEC filing cadence, Anixa Biosciences Inc. (ANIX)'s next quarterly reporting window is estimated around Jan 29, 2027.

How much is ANIX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ANIX, spanning a range between $2.73 and $3.51.

Direct Sub-Reports: ANIX RQD Cockpit ANIX 12M Forecast ANIX Earnings & Move ANIX Dividends & DRIP ANIX Insiders & 13F ANIX Whale Options ANIX Profit Sankey ANIX News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ANIX — Anixa Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:35Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns ANIX a score of 32 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the scores are:

Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -6.25%. For a prospective investor, this means the business is consuming cash rather than generating it, so any valuation rests on future outcomes not yet visible in reported results.
Whale 13F Flow: 5 / 20. The pillar label references institutional accumulation and options positioning. The underlying 13F holder detail is not available in source data, so the score cannot be traced to specific holders here.
Insider Conviction: 3 / 20. The pillar label references SEC Form 4 and Congressional PTR cluster flow. Recent news items describe insider purchases (see Recent Catalysts), which is a potential counterpoint, but the rating weights overall insider conviction as weak.
Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. A beta of 1.0 means the stock is expected to move broadly in line with the market; the pillar score reflects limited alignment with the prevailing regime as assessed by the rating.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. These point to a fragile financial position with limited cushion.

Investor implications: the upside case depends on a clinical or commercial inflection that the reported financials do not yet show. The valuation tradeoff is that the market capitalization of $114.7M is set against negative operating income and negative free cash flow, so the equity carries funding and dilution risk. The rating's overall verdict is a strong negative signal on forensic and cash-generation grounds.

Business

Anixa Biosciences Inc. (ANIX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it is a publicly traded biotechnology company with a market capitalization of $0.1B. Per the recent news wire, the company's stated focus includes CAR-T therapy for ovarian cancer and a breast cancer vaccine. The source data does not describe its customers or revenue model in detail; reported revenue is $0.0M for FY 2025 per the SEC financials.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-11.7M	$-10.9M	N/A	$-7.2M	$1.5M	N/A
FY 2024	$0.2M	$-13.8M	$-12.6M	N/A	$-7.3M	$1.1M	N/A
FY 2023	$0.2M	$-11.0M	$-9.8M	N/A	$-6.2M	N/A	N/A

Per the SEC financials, the company reported operating losses in each period shown, with revenue falling to $0.0M in FY 2025. Gross, operating, and net margins are each listed as 0% in the market data. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash was $1.5M at FY 2025 against a free cash flow outflow of $-7.2M.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the catalysts include:

A live investor webinar on CAR-T therapy for ovarian cancer and a first-in-class breast cancer vaccine (Yahoo Finance).
A report that four ovarian cancer patients lived over a year after the company's experimental treatment (Stock Titan).
Insider activity: a director's purchase of 8,000 shares at $2.98 per share (Stock Titan), and reports of insider Amit Kumar buying 8,000 and 5,000 shares (MarketBeat).
A MarketBeat item citing a consensus target price of $8.00.

All news items are tagged YELLOW with the impact label MARKET WIRE. Risk watch items: the cash balance of $1.5M is small relative to the FY 2025 free cash outflow of $-7.2M; the shares are down -5.45% on the day; and the stock trades near the low end of its 52-week range. The Butterfly Supply-Chain Graph contains no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Supply chain: NONE. Butterfly links: none. Proprietary signals: none. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be mapped from the source data. A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from partners, suppliers, or customers. Watch items drawn from the other sections: dependence on external funding given negative free cash flow, and the sensitivity of clinical-stage sentiment to news flow described above.

Open Questions

What is the company's cash runway given $1.5M cash against a $-7.2M FY 2025 free cash outflow, and how is it being funded?
What is the debt position, since debt is reported as N/A in every period?
What is the status and timeline of the CAR-T and breast cancer vaccine programs referenced in the news wire?
Why are EPS and valuation multiples unavailable, and what share count underlies the $114.7M market capitalization?
What are the identities and holdings of institutional and insider holders behind the cited purchases?

ANIX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Anixa Biosciences Inc. (ANIX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ANIX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 6h ago

Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine

Yahoo Finance report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 9h ago

Anixa Biosciences Inc (NASDAQ:ANIX) Stock Has Consensus Target Price of $8.00

MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 12h ago

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 15h ago

Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Amit Kumar Purchases 8,000 Shares

MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

At $2.98 a share, a director buys 8,000 Anixa Biosciences (ANIX) shares.

Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 21h ago

Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Amit Kumar Buys 5,000 Shares

MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

CEO Amit Kumar buys 8,000 Anixa Biosciences (ANIX) shares, bringing his direct holdings to 680,000.

Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

At $3.17 a share, Anixa Biosciences (ANIX) CEO Amit Kumar buys 5,000 shares.

Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANIX Bull vs. Bear Conversation Board — What's Your Call at $3.12?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANIX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.75 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ANIX (E • RQD 32/100) a Buy at $3.12?

Welcome to the ANIX (Anixa Biosciences Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.59 (-17.0%)

Spot @ $3.12

Pump the brakes on ANIX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ANIX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Anixa Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.90 (+25.0%)

Spot @ $3.12

ANIX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ANIX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.12 (52-wk range $2.32 - $5.46), any beat on forward guidance forces shorts and underweight funds to chase.